LUND – December 2, 2009. DermaGen AB – part of the Karolinska Development dermatology and wound healing company “Pergamum” – today announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin disease where dry skin and the skin’s weakened barrier function make patients susceptible to colonization by microorganisms, a triggering or exacerbating factor of the disease. The AMP has shown a broad spectrum of activity and is both bactericidal and fungicidal. In the clinical trial, the company’s candidate drug clearly reached its primary objective, demonstrating a significant reduction of total microbes in eczemas compared to placebo. In addition to good safety and tolerability performance, the candidate drug also showed a trend towards improved eczema status. This is the first time a study has shown efficacy of AMPs for atopic dermatitis in man.
Read the full article in the attached PDF-file below:
Click here
The study is composed of two parts; an open safety and local tolerability part and a 1:1 randomized, double-blind efficacy part comparing DPK-060 treatment against a placebo. The study encompasses patients with atopic dermatitis and initial analysis of patient data has already begun.
The primary endpoint of the study is to measure the reduction of microbes in the treated eczemas after DPK-060 therapy compared with placebo treatment. Secondary clinical endpoints in the study include documentation of clinical score of the eczema during and after treatment, safety and local tolerability.
The results from the study are expected to be released in Q3 of 2009.
For more information about DermaGen AB please visit www.dermagen.se
Or contact:
Dr. Jan Alenfall, CEO
Phn: + 46 (0)46 192 197
Mob: + 46 (0)709 315 115
E-mail: jan.alenfall@dermagen.se
Please visit us at the Karolinska Development Pavilion, booth #5901 or
contact DermaGen for arranging personal meetings.
2009-03-04 - DermaGen sponsors The 2009 Gordon Conference on Antimicrobial PeptidesDermaGen AB is sponsoring The 2009 Gordon Conference on Antimicrobial Peptides being held in Ventura, California, on March 1-6, 2009.
The Conference will present the latest research on the biology and activities of antimicrobial peptides, essential and multifunctional host defense molecules employed by all organisms for innate defense. A wide range of topics will be discussed, such as structure/function analysis, regulation of expression, mechanisms of action, microbial avoidance strategies, human disease associations and model systems, and development of antimicrobial peptides as therapeutics.
Leaders in the field
Invited speakers represent a diverse variety of scientific disciplines, including biochemistry, molecular genetics, microbiology, animal and plant biology, structural biology, medicine, innate immunity, signaling, and drug development. The Conference will bring together a collection of investigators who are at the forefront of their field, and will provide opportunities for junior scientists and graduate students to present their work in poster format and exchange ideas with leaders in the field. Some abstracts and poster presenters will be selected for short talks.
An avenue for scientists
The collegial atmosphere of this Conference, with programmed discussion sessions as well as opportunities for informal gatherings in the afternoons and evenings, provides an avenue for scientists from different disciplines to brainstorm and promotes cross-disciplinary collaborations in the various research areas represented.
To see the Conference program, topics and the speakers, please visit:
http://www.grc.org/programs.aspx?year=2009&program=antimicr
For more information on DermaGen AB please visit www.dermagen.se
or contact:
Dr. Jan Alenfall, CEO
Phn: + 46 (0)46 192 197
Mob: + 46 (0)709 315 115
E-mail: jan.alenfall@dermagen.se
In line with its growth and expanded business activities, DermaGen AB has recently launched its new website. Both the design and content have been enhanced to make the site more attractive to readers and provide them with in-depth information. Features that have been addressed are:
Graphic design – taking an up-to-date approach to graphic design now gives our website a fresh look with eye-catching colors and nice-looking layout. Additional decorative pictures and other graphic content make a visit much more interesting.
Web structure – This has been expanded to give the reader a lot more information. The main menu titles of Company and Technology have now been supplemented with The Challenge, Indications, Product development and Business Model.
Information content – essentially the content has been upgraded to provide the depth of information that those interested in antimicrobial peptides for topical application would expect to find. In addition to the scientific content, the business model now gives potential investors and inventors better information about how they can become involved in partnerships, licensing and collaboration.
We hope that all who visit www.dermagen.se will agree with us that the new website is one to be proud of.
For more information on DermaGen AB contact:
Dr. Jan Alenfall, CEO
Phn: + 46 (0)46 192 197
Mob: + 46 (0)709 315 115
E-mail: jan.alenfall@dermagen.se